Indication intelligence, analysis and sector perception

The Biostage (BSTG) Chronicles: filed an S-1 preliminary offering prospectus by Newbridge Securities Corporation.

June 23, 2022 5:21pm

Very lucky, BSTG settled terminal death suit as Dr. Paolo Macchiarini was found criminally liable in Swedish court for causing felony bodily injury to a patient, he had fitted with one of the artificial windpipes.

With a three (3) year-old IND and multiple, and more Private Placements (PPM) that have funded WHAT?

Who or whom U.S. investors invest in this equity are backing the wrong horse or just putting lipstick on a pig?

Where did it all start; with CEO and founder David Green "ensnaring and entangling" BSTG with a terminal death suit “supplying” Paolo Macchiarini; an Italian doctor who made headlines for pioneering windpipe surgery has gone on trial in Sweden, charged with aggravated assault for performing the experimental procedure.

Scandal for the ages! Dr. Paolo Macchiarini was found criminally liable in Swedish court for causing felony bodily injury to a patient he had fitted with one of the artificial windpipes seeded with #stemcells at Karolinska Institute. He received a “conditional,” or suspended, sentence.

Any comment from BSTG, David Green, Interim CEO, Chairman and former (at time) CEO ...who introduced Paolo Macchiarini to Harvard Apparatus Regenerative Technology now Biostage (BSTG)

Even more questions of corporate attrition NEED answers … I’ve read comments on trading websites that question WHY hasn’t there been more communication from the company and when will the BSTG website be updated.

Consider the attrition rate of the past five (5) years: two (2) CEOs, one (1) CMO who became president, one (1) CFO, one (1) interim CFO who walked-out over irregularities in an audit review, three (3) controllers, a VP of Finance who left without notice and reappeared as a consultant, five (5) members of the board of directors of which three (3) were on the audit committee, three (3) other operating VPs and twenty (20) scientific employees.

Is there a pattern here … and WHO is left with biotech experience to focus the clinical trials that have YET to be initiated after an IND approval?

All the while, Biostage (BSTG) is STILL not in good standing with a “going concern” designation.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

8 hours 32 min ago
RegMed Investors’ (RMi) pre-open: It’s “make” a buck day!

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.